NCT05599997View on ClinicalTrials.gov

A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

January 22, 2021

Study Completion Date

May 18, 2021

Conditions
Congestive Heart FailureRenal Impairment
Interventions
DRUG

Pecavaptan (BAY1753011)

30 mg, immediate release tablet, single dose, oral

DRUG

Pecavaptan (BAY1753011)

15 mg, immediate release tablet, single dose, oral

Trial Locations (2)

24105

CRS Clinical-Research-Services Kiel GmbH, Kiel

81241

APEX GmbH, München

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05599997 - A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney Function | Biotech Hunter | Biotech Hunter